Certara's Better Drug Discovery and Development Process
The drug discovery and development process is long and expensive with more failures than successes. At Certara, we anticipate and address your critical drug discovery and development risks and decisions using biosimulation and tech-enabled services.
In 2020, more than 1,650 customers worldwide chose Certara as their trusted partner for our gold-standard biosimulation software and tech-enabled services. As your trusted partner, we support confident decision-making throughout the entire biopharma R&D process to reduce cycle times, lower costs, and improve outcomes for patients.
Additionally, 17 global regulatory agencies have adopted our Phoenix™ PK/PD and/or Simcyp™ PBPK Simulator software platforms, including the US FDA and EMA.
We are proud to say that our customers, who use our biosimulation software and services, have received over 90% of all new drug approvals by the FDA since 2014.
How we help our clients
Latest from Certara
Pediatric Symposium October 28-29
Certara to Host Inaugural Symposium Dedicated to Advancing Pediatric Drug Development
Certara’s Simcyp™ COVID-19 Vaccine Model Named Finalist in Both the 2021 Citeline Awards and R&D 100 Awards
On Demand Webinar
Simplify Your Submissions Review Process With an Anytime, Anywhere eCTD Viewer
Case Study: Transparency & Disclosure
Certara|Synchrogenix Guides Company to Transparency and Disclosure Succes
Article: Technology Networks
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines
Article: Pharmacy Times
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline
Building a Robust Clinical Pharmacology & Model-Informed Drug Development Strategy for New Alzheimer’s Disease Drugs
Case Study: PPL and narrative templates
Complex patient profile and narrative template needs
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling & Simulation
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation